The TLR4 agonist G100 is a fully synthetic analogue of bacterial lipopolysaccharides (LPS) and has been tested intratumorally in patients with Merkel cell carcinoma; because TLR4 is involved in septic shock, systemic administration of its agonist could be dangerous. Here, TLR4 is linked to Merkel cell skin cancer.